Senya secured a £680,000 non-dilutive grant from the highly competitive Innovate UK Investor Partnerships scheme for our preclinical work in nephrology and oncology. This is…
Read More
Senya Therapeutics
About Us
Senya Therapeutics is a newly formed spinout of University College London based in Central London. We have inherited data, knowhow and an extensive portfolio of patents related to a novel target called glycoprotein leucine-rich α-2 glycoprotein 1 (LRG1). Our co-founders, Professors John Greenwood and Steve Moss are world authorities on LRG1.
LRG1 is highly expressed in patients with Chronic Kidney Disease (CKD) where it is a validated prognostic biomarker and promotes vascular dysfunction and fibrosis. LRG1 is also overexpressed in many solid cancers leading to tumour growth and drug resistance. Senya’s academic founders have shown that inhibition of LRG1 increases efficacy of anti-PD-1 therapies in mouse melanoma and lung models. External academics have proven that LRG1 blockage attenuates kidney dysfunction in mouse models.
Senya is developing first-in-class LRG1-inhibitors. Our lead compound STX-002 is near-IND. STX-002 is a high affinity, humanised, full-length function-blocking LRG1 antibody and has shown efficacy as a monotherapy. Senya aims to start clinical trials for CKD and cancer in the next 24 months.
Our Investors
News
April 2023 Senya has signed a Memorandum of Understanding with the Netherlands Cancer Institute in collaborating for Phase I/II trial in cancer using STX-002, Senya’s…
Senya Therapeutics is launched with a primary focus on developing STX-002, its lead compound, for chronic kidney disease and immuno-therapy resistant tumours.
